Premium
Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma
Author(s) -
Hsueh Chuen,
Lin JenDer,
Wu IChin,
Chao TzuChieh,
Yu JauSong,
Liou MiawJene,
Yeh ChiJu
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21844
Subject(s) - medicine , thyroid cancer , thyroid carcinoma , angiogenesis , thyroid , immunostaining , angiopoietin , cancer , stage (stratigraphy) , papillary thyroid cancer , pathology , vascular endothelial growth factor , immunohistochemistry , oncology , vegf receptors , paleontology , biology
Abstract Aims Angiogenesis from thyroid cancer cell plays the important roles in post‐surgical persistent, recurrent, and metastatic papillary thyroid cancer (PTC). This study is to investigate the expression of angiopoietin‐1 (Ang‐1), angiopoietin‐2 (Ang‐2), Tek/Tie‐2 receptor, and vascular endothelial growth factors (VEGF) in normal, benign thyroid tissues and different stage of PTC. We expect angiogenetic factors are important in the presentation of local‐regional neck or distant metastases in PTC. Materials and Results A total of 101 tissues from the subjects underwent thyroidectomy were enrolled in the study. There were 22 control and 79 thyroid cancer patients in different TNM stagings were collected. Ang‐1 illustrated highest mean immunostaining score in metastatic group. Comparing with normal and benign thyroid tissues, thyroid cancer tissues illustrated significantly high expression of three angiogenetic factors and Tie‐2 receptor. Of the PTC, significantly high expression of three angiogenetic factors and Tie‐2 receptor were illustrated in recurrent cases. VEGF showed statistical difference in disease‐free cancer mortality, and recurrent groups. Conclusions Immunochemical staining illustrated VEGF, Ang‐1, Ang‐2 expression in PTC tissues related to clinical staging; however, we need more information concerning these factors with long‐term follow‐up results. J. Surg. Oncol. 2011; 103:395–399. © 2010 Wiley‐Liss, Inc.